Articles matching the ‘HIV’ Category

RSS

January 18th, 2016

IV and Injectable HIV Treatments Are Much Discussed — But Won’t Be Here Anytime Soon

Something interesting happens when you poll people who treat HIV — and people who have HIV — about whether they’d prefer a treatment option that consists of a periodic injection or infusion in place of the pill or pills that they take every day. Lots of them say yes. Even people who are taking just one pill […]


January 10th, 2016

Medical Marijuana and Painful Neuropathy — An Opportunity to Make Us Believers

Medical marijuana is now officially available in New York, the city with by far the largest number of people living with HIV/AIDS in the country. Reporting on the first dispensary in Manhattan, the aptly named Julie Weed (yes! her real name!) writes: One of the most promising areas for research is the substitution of medical marijuana for […]


November 26th, 2015

Five (OK, Six) ID/HIV Things to be Grateful for this Holiday Season, 2015 Edition

Some quick ID/HIV gratitude items for 2015, done rapidly as we’re hosting a big meal later today. I wonder what that might be. New Ebola virus disease cases and deaths have dramatically declined. I write that sentence with some trepidation, as cases continue to occur sporadically, and this late relapse in a nurse was a chilling reminder of […]


November 22nd, 2015

Just Wondering: Quick ID Questions to Consider

Several quick ID queries, some of them answerable on the Google machine — but I’m not going there. Too busy laundering my white coat! What ever happened to amphotericin A? What’s the difference between a “serovar” and a “serotype”? Do dogs feel bad that Pasteurella multocida is more famous than Capnocytophaga canimorsus? Colistin resistance is bad — but how often does colistin actually work […]


November 8th, 2015

New HIV Treatment “ECF-TAF” is Really All About the “TAF” Part

HIV providers and patients recently got this news from the FDA: The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. (Disclosure:  I have been […]


October 29th, 2015

The Most Important HIV Study at IDWeek 2015

After reporting my choice for the most important HIV study at ICAAC, I received this email from a colleague: If that’s the most important study, I really didn’t miss much … Now she has notoriously high standards — hard to impress her — but her opinion notwithstanding, I still think the STRIIVING study has some important messages we can apply […]


October 13th, 2015

Yes, There Are Important HIV Studies at ICAAC and IDWeek — Here’s One

Both ICAAC and IDWeek (formerly IDSA) are now over, IDWeek ending this past Sunday. These are the two large Infectious Diseases scientific meetings that take place each year in the Fall. They’ve been battling it out for years for attendance, but it looks like finally IDWeek (formerly IDSA) has won the Fall slot — ICAAC is moving next year to […]


September 24th, 2015

Decision to Lower Price of Pyrimethamine a Good One, Especially Given the Weak Defense of the Price Hike

The big ID story the past couple of weeks is that the price of pyrimethamine — a drug that’s been available generically for decades — went from $13.50 to $750 for one pill after the exclusive rights to the drug were purchased by Turing Pharmaceuticals. Now, after a barrage of criticism — all the way from this […]


September 20th, 2015

EHR and Drug Prescribing Warnings: The Good, the Bad, the Ugly

Part 1. The Good. Recently, an ENT colleague (fictionally named “Clint” below), sent me two emails triggered by drug-drug interaction warnings he received while seeing HIV patients. Here’s #1: Hey Paul, I saw Mark C yesterday for hoarseness, and his exam was negative. Thought we’d try a PPI for reflux, but when I wrote the script, I […]


September 7th, 2015

Two Drugs with High Prices — One is (Surprise!) Good Value, The Other is Truly a Rip-off

By now, the fact that HCV treatment carries a high price is a fact as well known to the medical and non-medical public as 1) a million dollars doesn’t get you much in Manhattan or Bay-area real estate; 2) a Rolex is an expensive way to know what time it is; and 3) even though […]


HIV Information: Author Paul Sax, M.D.

Paul E. Sax, MD

Contributing Editor

NEJM Journal Watch
Infectious Diseases

Biography | Disclosures | Summaries

Learn more about HIV and ID Observations.